title: Collagen I enhances functional activities of human monocyte-derived dendritic cells via discoidin domain receptor 2.
abstract: We evaluated the involvement of collagen and their discoidin domain receptors (DDRs), DDR1 and DDR2, on the activation of human monocyte-derived dendritic cells (hDCs). DDR2 was markedly expressed on mature hDCs in comparison to immature ones. Collagen I enhanced the release of IL-12p40, TNF-α and IFN-γ by hDCs. Additionally, hDCs exhibited enhanced expression of costimulatory molecules, and potent functional activities which, in turn, has therapeutic value. Interestingly, DDR2 depletion showed decrease in capacity of hDCs to stimulate T cells proliferation, whereas DDR1 silencing had no significant affect. These data demonstrate that DDR2 enhances hDCs activation and contributes to their functional activities. In addition, application of collagen I treated dendritic cells (DCs) vaccine reduced tumor burden giving longer survival in melanoma mice. Our study suggests that collagen I may enhance functional activities of DCs in immune response.
authors.affiliation: Department of Immunolgy and Institute of Medical Sciences, Chonbuk National University Medical School, Jeonju, Jeonbuk 561-756, Republic of Korea.
authors.forename: Barun
authors.initials: B
authors.lastname: Poudel
authors.forename: Dong-Sik
authors.initials: DS
authors.lastname: Yoon
authors.forename: Jeong-Heon
authors.initials: JH
authors.lastname: Lee
authors.forename: Young-Mi
authors.initials: YM
authors.lastname: Lee
authors.forename: Dae-Ki
authors.initials: DK
authors.lastname: Kim
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use; D002454:Cell Differentiation; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D024042:Collagen Type I / Q000276:immunology* / Q000494:pharmacology; D003713:Dendritic Cells / Q000166:cytology / Q000187:drug effects / Q000276:immunology* / Q000637:transplantation; D000070819:Discoidin Domain Receptor 1; D000070818:Discoidin Domain Receptors; D005260:Female; D015870:Gene Expression / Q000187:drug effects / Q000276:immunology; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis / Q000276:immunology; D053762:Interleukin-12 Subunit p40 / Q000096:biosynthesis / Q000276:immunology; D008546:Melanoma, Experimental / Q000276:immunology / Q000473:pathology / Q000517:prevention & control; D051379:Mice; D008810:Mice, Inbred C57BL; D009000:Monocytes / Q000166:cytology / Q000276:immunology; D034741:RNA, Small Interfering / Q000235:genetics; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000276:immunology*; D011975:Receptors, Mitogen / Q000037:antagonists & inhibitors / Q000235:genetics / Q000276:immunology*; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis / Q000276:immunology
chemical_list: D019496:Cancer Vaccines; D024042:Collagen Type I; D053762:Interleukin-12 Subunit p40; D034741:RNA, Small Interfering; D011975:Receptors, Mitogen; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma; C092030:DDR1 protein, human; D000070819:Discoidin Domain Receptor 1; D000070818:Discoidin Domain Receptors; D020794:Receptor Protein-Tyrosine Kinases